RESUMEN
The Centers for Disease Control and Prevention (CDC) Quarantine Stations distribute select lifesaving drug products that are not commercially available or are in limited supply in the United States for emergency treatment of certain health conditions. Following a retrospective analysis of shipment records, the authors estimated an average of 6.66 hours saved per shipment when drug products were distributed from quarantine stations compared to a hypothetical centralized site from CDC headquarters in Atlanta, GA. This evaluation supports the continued use of a decentralized model which leverages CDC's regional presence and maximizes efficiency in the distribution of lifesaving drugs.
Asunto(s)
Centers for Disease Control and Prevention, U.S. , Urgencias Médicas , Tratamiento de Urgencia/métodos , Sistemas de Medicación , Cuarentena/métodos , Reserva Estratégica , Centers for Disease Control and Prevention, U.S./organización & administración , Centers for Disease Control and Prevention, U.S./estadística & datos numéricos , Control de Formularios y Registros , Humanos , Sistemas de Medicación/organización & administración , Sistemas de Medicación/estadística & datos numéricos , Modelos Organizacionales , Evaluación de Programas y Proyectos de Salud , Reserva Estratégica/métodos , Reserva Estratégica/organización & administración , Factores de Tiempo , Transportes , Estados UnidosRESUMEN
The Centers for Disease Control and Prevention (CDC) Quarantine Stations distribute select lifesaving drug products that are not commercially available or are in limited supply in the United States for emergency treatment of certain health conditions. Following a retrospective analysis of shipment records, the authors estimated an average of 6.66 hours saved per shipment when drug products were distributed from quarantine stations compared to a hypothetical centralized site from CDC headquarters in Atlanta, GA. This evaluation supports the continued use of a decentralized model which leverages CDC's regional presence and maximizes efficiency in the distribution of lifesaving drugs.
Asunto(s)
Centers for Disease Control and Prevention, U.S. , Urgencias Médicas , Hospitales de Aislamiento , Preparaciones Farmacéuticas/provisión & distribución , Transportes/estadística & datos numéricos , Antimaláricos/provisión & distribución , Artemisininas/provisión & distribución , Artesunato , Antitoxina Botulínica , Antitoxina Diftérica , Georgia , Humanos , Factores Inmunológicos/provisión & distribución , Estudios Retrospectivos , Factores de Tiempo , Tiempo de Tratamiento , Estados UnidosRESUMEN
BACKGROUND: Japanese encephalitis (JE) vaccine is recommended for travelers to Asia whose itineraries increase their risk of exposure to JE virus. The numbers of travelers with such itineraries and the proportion of those who receive JE vaccine are unknown. We performed a survey to estimate the proportion of US travelers to Asia who receive JE vaccine according to the Advisory Committee on Immunization Practices (ACIP) recommendations. METHODS: We surveyed US residents ≥ 18 years old departing on 38 flights to Asia selected through a stratified random sample of all direct flights to JE-endemic countries from three US airports. We asked participants about planned itineraries and activities, sources of travel health information, JE vaccination status, and potential barriers to vaccination. Participants planning to spend ≥ 30 days in Asia or at least half of their time in rural areas were defined as "higher JE risk" travelers for whom vaccination should have been considered. RESULTS: Of 2,341 eligible travelers contacted, 1,691(72%) completed the survey. Among these 1,691 participants, 415 (25%) described itineraries for which JE vaccination should have been considered. Of these 415 higher JE risk travelers, only 47 (11%) reported receiving ≥ 1 dose of JE vaccine. Of the 164 unvaccinated higher JE risk travelers who visited a health care provider before their trip, 113 (69%) indicated that they had never heard of JE vaccine or their health care provider had not offered or recommended JE vaccine. CONCLUSIONS: A quarter of surveyed US travelers to Asia reported planned itineraries for which JE vaccination should have been considered. However, few of these at-risk travelers received JE vaccine.
